Description: Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, Mass., and its cell processing facility in Louisville, Ky
Home Page: talaristx.com
TALS Technical Analysis
570 South Preston Street
Louisville,
KY
40202
United States
Phone:
502 398 9250
Officers
| Name | Title |
|---|---|
| Mr. Scott Requadt J.D., L.L.B., M.B.A., MBA | Pres, CEO, Sec. & Director |
| Dr. Suzanne T. Ildstad M.D. | Founder, Member of Scientific Advisory Board, Sr. Scientific Advisor & Director |
| Ms. Nancy Krieger M.D. | Chief Medical Officer |
| Ms. Mary Kay Fenton | CFO & Treasurer |
| Mr. Michael Zdanowski | Chief Technology Officer |
| Ms. Suzanne Tollerud | VP of Corp. Devel. |
| Mr. Andrew Clyde Farnsworth | Chief HR Officer |
| Mr. Eric Gornstein | Head of New Product Planning |
| Ms. Farah Natoli | Head of Portfolio & Program Management |
| Mr. Colby Suire Ph.D. | Head of R&D |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2762 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-05-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 131 |